Avadel Pharmaceuticals (NASDAQ:AVDL – Get Rating) had its price objective boosted by analysts at Needham & Company LLC from $8.00 to $9.00 in a note issued to investors on Monday, The Fly reports. The firm currently has a “buy” rating on the stock. Needham & Company LLC’s price target points to a potential upside of 12.78% from the company’s current price.
Other equities research analysts have also recently issued research reports about the stock. SVB Leerink upped their price target on shares of Avadel Pharmaceuticals from $6.00 to $12.00 and gave the stock an “outperform” rating in a research report on Thursday, August 11th. Craig Hallum reduced their price objective on shares of Avadel Pharmaceuticals from $15.50 to $12.00 and set a “buy” rating for the company in a research note on Thursday, July 28th. Finally, Jefferies Financial Group lowered shares of Avadel Pharmaceuticals from a “buy” rating to a “hold” rating and boosted their price objective for the stock from $6.00 to $8.00 in a research note on Wednesday, August 10th. Two equities research analysts have rated the stock with a hold rating and four have given a buy rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $10.29.
Avadel Pharmaceuticals Price Performance
Shares of AVDL opened at $7.98 on Monday. The company has a 50 day moving average price of $6.12 and a 200-day moving average price of $5.01. Avadel Pharmaceuticals has a fifty-two week low of $1.05 and a fifty-two week high of $10.00. The stock has a market capitalization of $477.15 million, a PE ratio of -3.58 and a beta of 1.52. The company has a debt-to-equity ratio of 2.11, a quick ratio of 2.73 and a current ratio of 2.73.
Institutional Trading of Avadel Pharmaceuticals
Avadel Pharmaceuticals Company Profile
Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is FT218, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness and cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017.
- Get a free copy of the StockNews.com research report on Avadel Pharmaceuticals (AVDL)
- After Nixing its 13% Dividend, Is Lumen Technologies Okay To Own?
- The Sell-Side Caps Gains In Dick’s Sporting Goods
- Cisco Systems Hopes Restructuring Cuts Costs to Drive Revenue
- Stock-ing Stuffers: 3 Attractive Stocks Trading Around $10
- Want to Get a 10% Dividend Yield, Look Here
Receive News & Ratings for Avadel Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avadel Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.